Notably, The Cancer Genome Atlas (TCGA) analysis of patient samples of several cancer types also revealed that relatively high expression of the miR-371-3p target PRDX6, but not PLCβ4 or STX12, significantly correlated with poor prognosis in lung adenocarcinoma, colorectal, gastric and breast cancer patients (Fig. 4f; Supplementary Figs 8 and 9). Here, PRDX6 is linked to breast carcinoma.